Virginia Commonwealth University

VCU Scholars Compass
Psychology Publications

Dept. of Psychology

2015

Electronic cigarettes and nicotine dependence:
evolving products, evolving problems
Caroline O. Cobb
Virginia Commonwealth University, cobbco@vcu.edu

Peter S. Hendricks
University of Alabama - Birmingham

Thomas Eissenberg
Virginia Commonwealth University, TEissenb@VCU.edu

Follow this and additional works at: http://scholarscompass.vcu.edu/psyc_pubs
Part of the Psychology Commons
Copyright © 2015 Cobb et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated.

Downloaded from
http://scholarscompass.vcu.edu/psyc_pubs/21

This Article is brought to you for free and open access by the Dept. of Psychology at VCU Scholars Compass. It has been accepted for inclusion in
Psychology Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Cobb et al. BMC Medicine (2015) 13:119
DOI 10.1186/s12916-015-0355-y

Promise vs perils of electronic cigarettes
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Electronic cigarettes and nicotine dependence:
evolving products, evolving problems
Caroline O Cobb1, Peter S Hendricks2 and Thomas Eissenberg1*

Abstract
Electronic cigarettes (ECIGs) use an electric heater to aerosolize a liquid that usually contains propylene glycol,
vegetable glycerin, flavorants, and the dependence-producing drug nicotine. ECIG-induced nicotine dependence
has become an important concern, as some ECIGs deliver very little nicotine while some may exceed the nicotine
delivery profile of a tobacco cigarette. This variability is relevant to tobacco cigarette smokers who try to switch to
ECIGs. Products with very low nicotine delivery may not substitute for tobacco cigarettes, so that ECIG use is
accompanied by little reduced risk of cigarette-caused disease. Products with very high nicotine delivery may
make quitting ECIGs particularly difficult should users decide to try. For non-smokers, the wide variability of ECIGs on
the market is especially troublesome: low nicotine products may lead them to initiate nicotine self-administration
and progress to higher dosing ECIGs or other products, and those that deliver more nicotine may produce nicotine
dependence where it was not otherwise present. External regulatory action, guided by strong science, may be
required to ensure that population-level nicotine dependence does not rise.
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Background
Electronic cigarettes (ECIGs) use an electric heater to
aerosolize a liquid that usually contains some combination of propylene glycol, vegetable glycerin, flavorants,
and nicotine. Nicotine is a mild psychomotor stimulant
that supports repeated self-administration as well as the
development of drug dependence, a neurobiological
adaptation to repeated drug exposure that is manifested
behaviorally by compulsive drug self-administration, an
aversive withdrawal syndrome upon cessation, and an
inability to quit despite a desire to do so and repeated
cessation attempts [1,2]. There is an ongoing and lively
debate regarding the potential for ECIGs to influence
individual and public health for better [3,4] or for worse
[5-7]. This debate frequently highlights the effects that
ECIGs may have on cigarette smoking cessation and
initiation, and in those contexts has touched on the
impact of ECIGs on maintaining nicotine dependence
where it already exists (i.e., in current cigarette smokers)
or developing it where it does not (i.e., in never smokers
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or former smokers). The issue of ECIGs and nicotine
dependence has become increasingly important in
line with the rapid development of nicotine delivery
methods, with earlier models largely being ineffective
[8,9], and later models delivering nicotine to the user’s
bloodstream much in the same manner as the tobacco
cigarette [10] – a product optimally designed to increase
the likelihood of chronic use or dependence [11]. If this
evolution continues, ECIGs with a nicotine delivery profile that exceeds that of a tobacco cigarette may soon be
commonplace [12]. The availability of such products
may have profound effects for people who currently
smoke tobacco cigarettes, as well as those who do not.
Current smokers

For current tobacco cigarette smokers much has been
written about the potential benefits of ECIGs [13,14].
These individuals are almost certainly already dependent
on cigarette-delivered nicotine, and self-administer it via
toxicant-laden tobacco smoke that causes a variety of
lethal disorders including cancer, cardiovascular disease,
and pulmonary disease [11]. The potential benefit of
ECIGs for this population is that nicotine can be selfadministered in an aerosol that contains far fewer
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tobacco toxicants at lower levels than those found in tobacco smoke and thus may present a reduced health risk
[15], although the long-term health outcomes of chronic
ECIG use are unknown. For this potential of ECIGs to
be realized to its fullest extent, inhalation of toxic tobacco smoke must cease almost completely [16,17],
meaning that tobacco cigarette smokers must use ECIGs
as a total or near-total substitute for cigarette smoking.
Recent data indicate that ECIG use acts as a substitute
for cigarette smoking for some individuals, but not for
others [18]. Total substitution for the majority of
smokers may be more likely when ECIGs reliably approximate the nicotine delivery profile of a tobacco
cigarette the first time and every time they are used. If
ECIG producers are unwilling to ensure that their products perform in this manner, empirically-based ECIG
regulation may have an important role to play in ensuring safe and reliable nicotine delivery.
Importantly, ECIGs may continue to evolve such that
they exceed the nicotine delivery profile of a tobacco
cigarette. For ECIG producers, providing ever more
nicotine to already nicotine-dependent individuals may
be seen as a business growth opportunity: what better
way to escalate profits than to induce customers to use
more product compulsively? Obviously, if long-term
ECIG use is, at some point in the future, demonstrated
to cause adverse health consequences, this seeming
‘growth opportunity’ could be a public health disaster.
Less obviously, even if ECIG use causes no adverse
health consequences, there are still individual and societal harms associated with ever increasing levels of drug
dependence. Dependent individuals can spend inordinate resources on drug seeking and self-administration,
and prioritize these behaviors over occupational, familial,
and other obligations [2]. Consider that pathological
internet use, computer game-playing, and gambling represent problematic behaviors on the addictive spectrum
that are associated with few direct negative physical
health effects, yet important psychological and behavioral sequelae [19-21]. Put simply, there is no clear public health justification for the ready availability of ECIGs
that exceed the nicotine delivery profile of tobacco cigarettes. There is already evidence that ECIG use maintains some level of nicotine dependence [22,23], even
with products that likely do not deliver nicotine efficiently. If excessive nicotine delivery renders ECIG users
even more dependent and thus even more unable to quit
should they eventually decide to try, this additional loss of
control itself could become a legitimate public health concern. If ECIG producers are unwilling to ensure that their
products do not exceed the nicotine delivery profile of
tobacco cigarettes, empirically-based ECIG regulation may
have an important role to play in ensuring safe and reliable
nicotine delivery that does not exceed this profile.
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Current non-smokers

Non-smokers include never smokers and former
smokers, few of whom currently are nicotine dependent.
These individuals are already at risk for ECIG-initiated
nicotine dependence due to marketing methods that
may target them [24,25], nicotine-containing liquids that
mimic the flavors of highly palatable foods and drinks
[25,26], and relatively unrestricted ECIG access [27].
Survey data suggest that at least some non-smokers are
already experimenting with ECIGs [28-31]. The extent
to which this experimentation will become compulsive
use is unclear. If it does, all of the arguments above become more compelling. In addition to the risks associated with ECIGs that deliver nicotine at a rate above a
tobacco cigarette, ECIGs that deliver low levels of nicotine may function as the so-called ‘starter products’ common in the smokeless tobacco arena [32]. These starter
products allow nicotine-naïve users to self-administer
low doses of nicotine without experiencing drugmediated adverse side effects, and then, as tolerance
develops, they can ‘graduate’ to products that deliver increasing doses of the drug [32]. Thus, ECIGs that deliver
little nicotine might start nicotine-naïve users on the trajectory to compulsive nicotine use, whereas products
that deliver even more nicotine than a tobacco cigarette
have the potential to make ECIG cessation even more
difficult than smoking cessation. A similar line of reasoning follows for former smokers, who not only risk a
return to nicotine dependence via ECIGs, but also the
possibility of relapse to their previously-preferred nicotine self-administration method, the lethal tobacco
cigarette. If ECIG producers are unwilling to act so that
their products do not lead never-smokers and former
smokers into compulsive nicotine use, empirically-based
ECIG regulation may have an important role to play in
avoiding this outcome.

Conclusions
The evolution of the ECIG from a class of products that
failed to deliver nicotine to one that has the potential to
exceed the nicotine delivery of a tobacco cigarette is a
concern for all. This concern is not based on some ideological or moral position regarding drug dependence [4],
but rather on an understanding of the financial, behavioral, and social ramifications of compulsive drug use.
As others have suggested [4,13,14], ECIG use well may
be a method for achieving significant decreases in the
disability, disease, and death associated with combustible
tobacco use worldwide. Achieving these decreases may
require ECIGs that approach the nicotine delivery profile
of a tobacco cigarette, but likely do not require ECIGs
that exceed that profile. In addition, these decreases in
cigarette-caused morbidity and mortality must not be
accompanied by an increase in compulsive nicotine use
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among those who do not currently use the drug. A
profit-minded ECIG industry may require external regulatory force, guided by strong science, to ensure that
population-level nicotine dependence does not rise.
Relevant targets for further research and potential regulatory intervention include product characteristics [33]
and nicotine flux [34,35], as well as product advertising
and access [36]. In addition, this discussion has focused
exclusively on nicotine; regulation can also limit user
exposure to other ECIG toxicants, including those contained in the liquid [37,38] as well as those produced
when the liquid is heated [37,39,40].
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